Johnson & Johnson said on January 6 that a real-world study showed the company’s single shot Covid-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.

Immunology is one of the more complicated areas of the life sciences, and recent studies on the long-term efficacy of the mRNA vaccines against Covid-19 are prime examples of just how complicated it can be.

U.S. Food and Drug Administration scientists said on Sept. 15 that booster doses of Pfizer’s Covid-19 vaccine may not be needed, even though the third shot generates a higher immune response in recipients.

Swoop, a leader in AI-generated digital audiences for healthcare, announced the release of its newest product offerings that uncover optimal healthcare provider (HCP) influencers for life sciences companies.

Two very exciting areas where Artificial Intelligence (AI) is having an impact on the life sciences landscape are patient stratification and synthetic control arms. Recent data and technology advances are starting to yield compelling results, according to Derek Baird, President North America of Sensyne Health and Commercial Director of SENSE.

Real Chemistry’s IPM.ai, a leader in uncovering undiagnosed and misdiagnosed patients via machine learning, and Datavant, a leader in helping healthcare and life science organizations securely connect their data, announced an expanded partnership that will enable pharmaceutical and biotechnology companies to connect de-identified first-party data to IPM.ai’s real-world data universe.

Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.

Komodo Health and Klick Health on April 8 announced a strategic partnership making Klick the premier life sciences marketing agency to leverage Komodo’s Healthcare Map – a real-world data and analytics platform.

Sanofi and Translate Bio said on March 12 they had started a human trial of their mRNA Covid-19 vaccine candidate, the French drugmaker’s second vaccine project, which follows a protein-based shot hit by a delay during 2020.

Global health innovation leader W2O announced the acquisitions of tech-enabled companies Swoop and IPM.ai, further accelerating what is expected to be the company’s 20th consecutive year of double-digit revenue growth.